OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
18 mei 2009 - 23:45
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus publishes business update
Bericht
OctoPlus N.V. (“OctoPlus” or “the Company”) (Euronext: OCTO), today publishes a business update for the first quarter of 2009.
Highlights
Financial
• Successful equity raising of € 6 million with an international consortium of investors completed in February
• Revenue growth well on track with guidance for the full year of € 19 million
• Continued positive cash flow from operations
Operational
• Contract development service contract signed with Galapagos in February
• Seventh client signed drug delivery evaluation contract in April
• Phase IIb clinical study with Locteron® commenced by OctoPlus’ licensee Biolex in April
Strategy
• Ongoing success for OctoPlus’ new service-oriented strategy with growing interest for drug delivery technology evaluations
Outlook
• OctoPlus reiterates the expected 2009 revenues of approximately € 19 million
Gerelateerde downloads
Datum laatste update: 13 februari 2026